IL248156A - Method for making a peptibody composition and a method for preparing a reconstituted peptibody composition - Google Patents

Method for making a peptibody composition and a method for preparing a reconstituted peptibody composition

Info

Publication number
IL248156A
IL248156A IL248156A IL24815616A IL248156A IL 248156 A IL248156 A IL 248156A IL 248156 A IL248156 A IL 248156A IL 24815616 A IL24815616 A IL 24815616A IL 248156 A IL248156 A IL 248156A
Authority
IL
Israel
Prior art keywords
method
peptibody composition
reconstituted
preparing
making
Prior art date
Application number
IL248156A
Other languages
Hebrew (he)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US79399706P priority Critical
Priority to US11/788,697 priority patent/US9283260B2/en
Priority to PCT/US2007/009712 priority patent/WO2007124090A2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38625630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL248156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL248156A publication Critical patent/IL248156A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
IL248156A 2006-04-21 2016-09-29 Method for making a peptibody composition and a method for preparing a reconstituted peptibody composition IL248156A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US79399706P true 2006-04-21 2006-04-21
US11/788,697 US9283260B2 (en) 2006-04-21 2007-04-19 Lyophilized therapeutic peptibody formulations
PCT/US2007/009712 WO2007124090A2 (en) 2006-04-21 2007-04-20 Lyophilized therapeutic peptibody formulations

Publications (1)

Publication Number Publication Date
IL248156A true IL248156A (en) 2018-07-31

Family

ID=38625630

Family Applications (3)

Application Number Title Priority Date Filing Date
IL194653A IL194653A (en) 2006-04-21 2008-10-07 Lyophilized therapeutic peptibody formulations
IL224966A IL224966A (en) 2006-04-21 2013-02-27 Lyophilized therapeutic peptibody formulations
IL248156A IL248156A (en) 2006-04-21 2016-09-29 Method for making a peptibody composition and a method for preparing a reconstituted peptibody composition

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL194653A IL194653A (en) 2006-04-21 2008-10-07 Lyophilized therapeutic peptibody formulations
IL224966A IL224966A (en) 2006-04-21 2013-02-27 Lyophilized therapeutic peptibody formulations

Country Status (38)

Country Link
US (2) US9283260B2 (en)
EP (6) EP2594286A1 (en)
JP (4) JP5432705B2 (en)
KR (2) KR101227278B1 (en)
CN (2) CN107789325A (en)
AR (1) AR060617A1 (en)
AU (1) AU2007240656A1 (en)
BR (1) BRPI0710508B1 (en)
CA (1) CA2649292C (en)
CR (3) CR20170130A (en)
CY (1) CY1118038T1 (en)
DK (1) DK2018183T3 (en)
EA (2) EA022424B1 (en)
ES (1) ES2599318T3 (en)
GE (1) GEP20156253B (en)
HR (1) HRP20161653T1 (en)
HU (1) HUE032144T2 (en)
IL (3) IL194653A (en)
JO (1) JO3324B1 (en)
LT (1) LT2018183T (en)
MA (1) MA30474B1 (en)
MX (1) MX2008013393A (en)
MY (1) MY162816A (en)
NO (1) NO20084893L (en)
NZ (1) NZ596367A (en)
PE (1) PE20081196A1 (en)
PH (1) PH12014502880A1 (en)
PL (1) PL2018183T3 (en)
PT (1) PT2018183T (en)
RS (1) RS55428B1 (en)
SG (2) SG10201501296SA (en)
SI (1) SI2018183T1 (en)
TN (1) TNSN08391A1 (en)
TW (1) TWI352598B (en)
UA (2) UA116080C2 (en)
UY (1) UY30302A1 (en)
WO (1) WO2007124090A2 (en)
ZA (1) ZA200808485B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00238B (en) 1998-10-23 2011-02-10 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
PL198123B1 (en) 1999-02-22 2008-05-30 University Of Connecticut Novel albumin-free factor viii formulations
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
PT1488806E (en) 1999-06-01 2016-02-26 Biogen Ma Inc A blocking monoclonal antibody to vla-1 and its use for the treatment of vascular disorders
CZ303450B6 (en) 2001-04-13 2012-09-19 Biogen Idec Ma Inc. Antibodies to VLA-1, composition containing such antibodies, nucleic acids encoding such antibodies, method of determining VLA-1 level and the use thereof when treating immunological disease
US7989160B2 (en) 2006-02-13 2011-08-02 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2648594C (en) 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
JO3324B1 (en) * 2006-04-21 2019-03-13 Amgen Inc Lyophilized Therapeutic Peptibody Formulations
JP5496658B2 (en) 2006-05-25 2014-05-21 バイオジェン・アイデック・エムエイ・インコーポレイテッド How to treat a stroke
US8999383B2 (en) 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
TR201900207T4 (en) * 2008-11-07 2019-02-21 Univ Connecticut Factor VIII Formulations
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
CA2787652C (en) * 2010-01-19 2015-06-02 Hanmi Science Co., Ltd. Liquid formulations for long-acting erythropoietin conjugate
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
SG190418A1 (en) 2010-12-02 2013-07-31 Oncolytics Biotech Inc Liquid viral formulations
WO2012075376A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
JP5759211B2 (en) * 2011-03-11 2015-08-05 三洋化成工業株式会社 freeze drying method
MX358726B (en) 2011-06-29 2018-09-03 Amgen Inc Predictive biomarker of survival in the treatment of renal cell carcinoma.
DE102011055889B4 (en) * 2011-11-30 2013-08-01 Otc Gmbh Process for the preparation of a protein hydrolyzate
CN102586217A (en) * 2011-12-16 2012-07-18 深圳市海普瑞药业股份有限公司 Freeze-drying preservation method for heparin flavobacterium heparinum heparinase I, II and III
RU2482128C1 (en) * 2011-12-28 2013-05-20 Замертон Холдингс Лимитед Peptides possessing cytoprotective activity
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
EP2644186A1 (en) * 2012-03-26 2013-10-02 OTC GmbH Hair conditioning composition for permanent and semi-permanent hair coloration applications
JP2015525748A (en) * 2012-06-25 2015-09-07 エマージェント プロダクト デベロップメント ゲイザーズバーグ インコーポレイテッド Temperature stable vaccine formulation
CA2928851A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
EP2968463A4 (en) * 2013-03-15 2016-11-23 Amgen Inc Myostatin antagonism in human subjects
CN104274827A (en) * 2013-07-01 2015-01-14 上海贺普药业股份有限公司 He Pula peptide preparation
WO2015035405A1 (en) * 2013-09-09 2015-03-12 Pinta Biotherapeutics, Inc. Myostatin antagonist for treatment of pew in esrd patients
US10383911B2 (en) * 2013-11-07 2019-08-20 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Storage stable lyophilized tripeptide formulations
BR112016012862A2 (en) * 2013-12-06 2017-09-26 Broad Inst Inc neoplasia vaccine formulations
US10357559B2 (en) 2013-12-27 2019-07-23 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
WO2015150968A2 (en) * 2014-03-29 2015-10-08 Intas Pharmaceuticals Ltd. Lyophilized pharmaceutical composition of fc-peptide fusion protein
EP3250191A1 (en) 2015-01-29 2017-12-06 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
SG11201609911YA (en) * 2014-05-28 2016-12-29 Nono Inc Chloride salt of tat-nr2b9c
EP3155008A4 (en) * 2014-06-13 2018-05-16 Santa Maria Biotherapeutics, Inc. Formulated receptor polypeptides and related methods
JP2017155046A (en) * 2017-04-05 2017-09-07 イーストポンド・ラボラトリーズ・リミテッド Cell hydration composition comprising cyclodextrin
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE3244265C2 (en) 1982-11-30 1991-11-21 Cassella Ag, 6000 Frankfurt, De
US4503235A (en) 1983-03-11 1985-03-05 Warner-Lambert Company Process for producing 4-carbamoyl-1H-imidazolium-5-olate
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
DE10399023I2 (en) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
JPH04218000A (en) 1990-02-13 1992-08-07 Kirin Amgen Inc Modified polypeptide
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AT240740T (en) 1991-03-15 2003-06-15 Amgen Inc Pegylation of polypeptides
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
WO1993024135A1 (en) 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5844929A (en) * 1994-02-24 1998-12-01 British Telecommunications Public Limited Company Optical device with composite passive and tapered active waveguide regions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU693478B2 (en) 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
IL116026A (en) 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
US5888763A (en) 1994-12-30 1999-03-30 The Rockefeller University Peptides specific for the first Crk-SH3 domain
EP0820299B1 (en) * 1995-02-06 2002-04-24 Genetics Institute, Inc. Formulations for il-12
IL113159D0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
WO1997004801A1 (en) * 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5746516A (en) 1995-08-11 1998-05-05 Hitachi Powdered Metals Co., Ltd. Porous bearing system having internal grooves and electric motor provided with the same
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
JPH09151200A (en) 1995-09-29 1997-06-10 Ajinomoto Co Inc Peptide capable of inducing immune response to human gastric cancer, therapeutic and preventive agent for human gastric cancer containing the same
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5714577A (en) 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
IL117223D0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
JP4088344B2 (en) 1996-03-28 2008-05-21 カイロン コーポレイション Peptide ligand of urokinase receptor
IL118003D0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
FR2748028B1 (en) 1996-04-30 1998-08-14 Lab Francais Du Fractionnement Peptides derived von Willebrand factor and of their use as an anticoagulant
CA2257108A1 (en) 1996-06-07 1997-12-11 Takeda Chemical Industries, Ltd. Novel peptides and production and use thereof
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE69734887D1 (en) 1996-09-10 2006-01-19 Burnham Inst La Jolla Tumor finding molecules, dividing conjugates, and method for use thereof
WO1998014476A1 (en) 1996-10-04 1998-04-09 Amgen Inc. Pharmaceutical compositions containing an mpl ligand
JP2001512560A (en) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ Methods and means for peptides and proteins selected having specific affinity for the target
WO1998033812A1 (en) 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
SI0975754T2 (en) 1997-04-16 2016-04-29 Amgen Inc., Osteoprotegerin binding proteins and receptors
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU1519799A (en) 1997-11-07 1999-05-31 Conjuchem, Inc. Salicylate derivatized therapeutic and diagnostic agents
AU2481399A (en) 1998-01-29 1999-08-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Variant peptide ligands that selectively induce apoptosis
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6235872B1 (en) 1998-03-12 2001-05-22 The Burnham Institute Proapoptotic peptides dependence polypeptides and methods of use
AU3189299A (en) 1998-03-20 1999-10-11 Chugai Pharmaceutical Co., Ltd. Peptide ligands for the erythropoietin receptor
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
AU744044B2 (en) 1998-04-06 2002-02-14 Advanced Immunit, Inc. Short peptides for treatment of neurological degenerative diseases
AT297762T (en) 1998-04-28 2005-07-15 Applied Research Systems Peg-lhrh analog conjugate
EP0972780A1 (en) 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides
AU764277B2 (en) 1998-05-22 2003-08-14 Abbvie Inc. Peptide antiangiogenic drugs
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
WO2000001402A1 (en) 1998-07-02 2000-01-13 Envision Biomedical Consulting Antiproliferative and antiviral proteins and peptides
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
US6906170B1 (en) 1998-08-21 2005-06-14 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides derived from IL-2 and analogues thereof
EA005005B1 (en) 1998-10-16 2004-10-28 Байоджен, Инк. HUMAN INTERFERON beta-1alpha HYBRID POLYPEPTIDE, MUTANTS THEREOF AND DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF
ME00238B (en) 1998-10-23 2011-02-10 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
AU2880400A (en) 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP2003533187A (en) * 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド Modified peptide comprising an Fc domain as therapeutic agents
US6853809B2 (en) 2001-01-30 2005-02-08 Koninklijke Philips Electronics N.V. Camera system for providing instant switching between wide angle and full resolution views of a subject
HU229910B1 (en) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks Peptides and related molecules that bind to tall-1
RU2180233C1 (en) 2001-06-26 2002-03-10 Общество с ограниченной ответственностью "Протеиновый контур" Method of recombinant protein liquid medicinal form preparing
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
WO2004019860A2 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
KR20130036378A (en) 2002-12-20 2013-04-11 암겐 인코포레이티드 Binding agents which inhibit myostatin
JP2008505928A (en) 2004-07-08 2008-02-28 アムジェン インコーポレーテッドAmgen Inc. Therapeutic peptide
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
JO3324B1 (en) * 2006-04-21 2019-03-13 Amgen Inc Lyophilized Therapeutic Peptibody Formulations
EP3035305B1 (en) 2014-12-18 2016-11-16 Axis AB Enclosure and arrangement for recess mounting of a camera or camera head

Also Published As

Publication number Publication date
WO2007124090A2 (en) 2007-11-01
US10166189B2 (en) 2019-01-01
TNSN08391A1 (en) 2010-04-14
EP2018183B1 (en) 2016-09-07
PT2018183T (en) 2016-12-02
CY1118038T1 (en) 2017-05-17
CA2649292C (en) 2017-01-17
MY162816A (en) 2017-07-31
HUE032144T2 (en) 2017-08-28
LT2018183T (en) 2016-11-25
ES2599318T3 (en) 2017-02-01
KR20090005204A (en) 2009-01-12
EP2018183A2 (en) 2009-01-28
EA201270625A1 (en) 2012-12-28
UA116080C2 (en) 2018-02-12
AU2007240656A1 (en) 2007-11-01
EP2594286A1 (en) 2013-05-22
TW200744624A (en) 2007-12-16
US9283260B2 (en) 2016-03-15
EA017085B1 (en) 2012-09-28
PE20081196A1 (en) 2008-09-04
BRPI0710508A2 (en) 2012-10-30
KR101236042B1 (en) 2013-02-21
JP5873854B2 (en) 2016-03-01
KR20120114384A (en) 2012-10-16
JP2014040441A (en) 2014-03-06
US20090258017A1 (en) 2009-10-15
SI2018183T1 (en) 2017-01-31
WO2007124090A3 (en) 2008-12-11
JO3324B1 (en) 2019-03-13
EP2594285A1 (en) 2013-05-22
EP2594288A1 (en) 2013-05-22
ZA200808485B (en) 2009-08-26
CN107789325A (en) 2018-03-13
KR101227278B1 (en) 2013-01-28
MA30474B1 (en) 2009-06-01
JP2018150380A (en) 2018-09-27
EP2594284A1 (en) 2013-05-22
NZ596367A (en) 2013-09-27
NO20084893L (en) 2009-01-20
CR20170130A (en) 2017-06-15
MX2008013393A (en) 2009-03-06
CR20140274A (en) 2014-07-18
UY30302A1 (en) 2007-10-31
JP2016065060A (en) 2016-04-28
US20160143852A1 (en) 2016-05-26
IL194653D0 (en) 2011-08-01
CA2649292A1 (en) 2007-11-01
GEP20156253B (en) 2015-03-10
JP2009534392A (en) 2009-09-24
PH12014502880A1 (en) 2016-01-18
DK2018183T3 (en) 2016-11-28
EA022424B1 (en) 2015-12-30
AR060617A1 (en) 2008-07-02
IL194653A (en) 2016-10-31
CN101484185A (en) 2009-07-15
PL2018183T3 (en) 2017-04-28
BRPI0710508B1 (en) 2018-10-23
UA99815C2 (en) 2012-10-10
EP2594287A1 (en) 2013-05-22
IL224966A (en) 2017-10-31
SG182887A1 (en) 2012-08-30
JP6356106B2 (en) 2018-07-11
RS55428B1 (en) 2017-04-28
EA200802170A1 (en) 2009-06-30
EP2594285B1 (en) 2016-08-10
JP5432705B2 (en) 2014-03-05
TWI352598B (en) 2011-11-21
CR10442A (en) 2009-02-19
SG10201501296SA (en) 2015-04-29
HRP20161653T1 (en) 2017-01-13

Similar Documents

Publication Publication Date Title
EP2089854A4 (en) Method for creating, manufacturing, and distributing three-dimensional models
AP200804716A0 (en) Rebaudioside a composition and method for purifying rebaudioside A
IL193565D0 (en) Immunogenic composition
GB0601961D0 (en) Method
IL203174A (en) Naphthalenecarnoxylate and phenylcarnoxylate derivatives and a method for preparing the derivatives
EP2086023A4 (en) Connected structure and method for manufacture thereof
EP2072018A4 (en) Implantation guide making method and guide block
EP2052109A4 (en) Improved compositions and processes for paper production
EP2235190A4 (en) Compositions and methods for producing isoprene
HK1185609A1 (en) Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof -2-
GB0624880D0 (en) Improved method for making analgesics
SI2137210T1 (en) Novel method and compositions
BRPI0912384A2 (en) composition and method for preparing a composition
PL2167005T3 (en) Fibrous structures and methods for making same
EP2055268A4 (en) Bone model, bone filler and process for producing bone filler
PL1856374T3 (en) A composition and method for making a proppant
PH12008500715B1 (en) Water dispersible composition and method for preparing same
SI1984006T1 (en) Conditioned blood composition and method for its production
PT1816117E (en) Method for manufacturing nitrobenzole
DK2253644T3 (en) Compositions and Methods for Preparing a Composition
EP1919897A4 (en) Method of preparing esomeprazole and salts thereof
GB0625995D0 (en) Method for preparing a composition
SI1982132T1 (en) Lyophilization method
HK1129415A1 (en) A composition and method for making a proppant
EP2087128A4 (en) Compositions and methods for immunodominant antigens

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed